购物车

全部删除
您的购物车当前为空

前往下单页继续购物

IL-17B Protein, Human, Recombinant (hFc) V2

一键复制产品信息

产品编号 TMPY-00400U

IL-17B Protein, Human, Recombinant (hFc) V2 is expressed in HEK293 Cells. The accession number is Q9UHF5.

IL-17B Protein, Human, Recombinant (hFc) V2

一键复制产品信息

产品编号 TMPY-00400U

IL-17B Protein, Human, Recombinant (hFc) V2 is expressed in HEK293 Cells. The accession number is Q9UHF5.

规格	价格	库存	数量

大包装 & 定制

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

资源下载

重组蛋白用户指南

产品信息

生物活性	Immobilized Human IL-17B, hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-IL-17B Antibody, hFc Tag with the EC50 of 18.0 ng/ml determined by ELISA.
产品描述	IL-17B Protein, Human, Recombinant (hFc) V2 is expressed in HEK293 Cells. The accession number is Q9UHF5.
种属	Human
表达系统	HEK293 Cells
蛋白编号	Q9UHF5
别名	ZCYTO7,NIRF,interleukin 17B,IL-20,IL-17B
蛋白构建	Gln21-Phe180
蛋白纯度	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
分子量	44.91 kDa (Predicted); 50-60 kDa (Due to glycosylation)
内毒素	< 1.0 EU/μg of the protein as determined by the LAL method.
蛋白性状	Lyophilized powder
缓冲液	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
存储	Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	IL-17A, the prototypic member of the IL-17 family, several experimental findings strongly support the role of the IL-17B/IL-17 receptor B (IL-17RB) pathway in tumorigenesis and resistance to anticancer therapies. IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies.